For many years, progress in stem cell medicine has been held back because of a lack of effective and efficient methods for the manufacture of therapeutic adult tissue stem cells. Massachusetts stem cell biotechnology company Asymmetrex announces this week that it now offers a new contract service that can help suppliers of therapeutic adult tissue
On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex led attendees at the 6th Annual Clinical Trials Supply New England 2017 conference in discussions about the need for quality controls for the supply of tissue stem cells used for treatments in either FDA-approved clinical trials or unregulated private stem cell clinics. Though these
Boston’s stem cell medicine biotechnology start-up Asymmetrex is beginning 2017 with exciting news for its recently launched contract service for counting adult tissue stem cells. The company’s webinar, produced with the international regenerative medicine social media network RegMedNet to describe Asymmetrex’s new counting technology and its applications, was 4th among the 10 most popular content
The biotech medicine world has been waiting to hear from new gene-editing companies exactly how they will go about turning the highly touted research advance into an effective medical advance. If reports about gene-editing company Intellia Therapeutics’ plan are any indication of the approach that will be taken, there is a rocky road ahead for
During the fall regenerative medicine and pharmaceutical conference seasons, Boston biotechnology company Asymmetrex, LLC will announce its new contract service for counting adult tissue stem cells. In three different conference venues, the company will relate how its new AlphaSTEM Test service can provide, for the first time, stem cell dose data for stem cell treatments
Asymmetrex Director Edits Newly Released Book on Human Stem Cell Toxicology Today, August 11, 2016, Royal Society of Chemistry Publishing in the UK released a new volume that is a first scholarly treatment of the emerging research and medical discipline of human stem cell toxicology. The 175 years old organization, which is the oldest
Asymmetrex continues to court gene-editing companies; Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics to name a few. Asymmetrex wants to dance with these companies into the new era of gene-editing therapeutics. Asymmetrex started pursuing them late in 2015. Today, the company announced that it would begin courting the companies’ scientists at conferences focused on gene-editing research and progress
Does Counting Adult Tissue Stem Cells Have a Human Impact? Asymmetrex’s 3-month campaign to increase awareness of the adult tissue stem cell counting problem has focused on how its AlphaSTEM technology solution could impact research and clinical practice. Now, the final post in the series answers the question, “Does counting adult tissue stem cells have
On March 22, Boston stem cell medicine technology start-up Asymmetrex will present a free, public, online webinar with the goal of discussing how it developed a stem cell technology that has been needed since the beginnings of stem cell biology. Hosted by RegMedNet, a London-based social media network for regenerative medicine professionals, the webinar will
In a RegMedNet post today (March 9, 2016), Asymmetrex explains that, although much attention is given to molecular genetics advances in the efficiency and integrity of new technologies for gene therapy, failure to count tissue stem cells is likely to limit future treatment success. Sufficient genetic engineering and transplantation of targeted tissue stem cells, like